title: Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.
authors.affiliation: *HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand †Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand ‡Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand §Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Anchalee
authors.initials: A
authors.lastname: Avihingsanon
authors.forename: Siraprapa
authors.initials: S
authors.lastname: Tongkobpetch
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Kerr
authors.forename: Baralee
authors.initials: B
authors.lastname: Punyawudho
authors.forename: Kanya
authors.initials: K
authors.lastname: Suphapeetiporn
authors.forename: Meena
authors.initials: M
authors.lastname: Gorowara
authors.forename: Kiat
authors.initials: K
authors.lastname: Ruxrungtham
authors.forename: Vorasuk
authors.initials: V
authors.lastname: Shotelersuk
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate; D005260:Female; D005820:Genetic Testing / Q000379:methods*; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use*; D010597:Pharmacogenetics / Q000379:methods; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use*; D000099148:UGT1A1 Enzyme
chemical_list: D019380:Anti-HIV Agents; D000069446:Atazanavir Sulfate; D014453:Glucuronosyltransferase; D009842:Oligopeptides; D011725:Pyridines; D000099148:UGT1A1 Enzyme